Publication: Emerging clinical applications of selected biomarkers in melanoma
Issued Date
2015-01-30
Resource Type
ISSN
11787015
Other identifier(s)
2-s2.0-84961290582
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical, Cosmetic and Investigational Dermatology. Vol.8, (2015), 35-46
Suggested Citation
Michael T. Tetzlaff, Carlos A. Torres-Cabala, Penvadee, Penvadee Pattanaprichakul, Ronald P. Rapini, Victor G. Prieto, Jonathan L. Curry Emerging clinical applications of selected biomarkers in melanoma. Clinical, Cosmetic and Investigational Dermatology. Vol.8, (2015), 35-46. doi:10.2147/CCID.S49578 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/36521
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Emerging clinical applications of selected biomarkers in melanoma
Other Contributor(s)
Abstract
© 2015 Tetzlaff et al. Melanoma is a lethal skin disease with a mostly predictable clinical course according to a known constellation of clinical and pathologic features. The distinction of melanoma from benign melanocytic nevus is typically unequivocol; however, there is a subset of tumors known for its diagnostic challenges, development of late metastases, and difficulties in treatment. Several melanocytic tissue biomarkers are available that can facilitate the histopathologic interpretation of melanoma as well as provide insight into the biologic potential and mutational status of this disease. This review describes the clinical application of some of these established and emerging tissue biomarkers available to assess melanocytic differentiation, vascular invasion, mitotic capacity, and mutation status. The selected tissue biomarkers in this review include MiTF, Sox10, D2-40, PHH3, H3KT (anti-H3K79me3T80ph), anti-BRAFV600E, and anti-BAP-1.